Simultaneous determination of metoprolol and α-hydroxymetoprolol in human plasma using excitation-emission matrix fluorescence coupled with second-order calibration methods

Bioanalysis. 2012 Dec;4(23):2781-93. doi: 10.4155/bio.12.265.

Abstract

Background: Metoprolol (MET) is a β1-adrenoceptor antagonist, which is widely used in the treatment of cardiovascular diseases, and α-hydroxymetoprolol (α-OHM) is its hydroxylated metabolite. Owing to their similar structures, optimization of the condition for the chromatography approach, which is in common use for determination, is both time consuming and laborious.

Results: A new and effective strategy that combines the excitation-emission matrix fluorescence with second-order calibration methods was developed for simultaneous determination of MET and α-OHM in human plasma.

Conclusion: Although the fluorescence spectra of MET and α-OHM overlapped and a large number of unknown and uncalibrated fluorescent components coexisted, the developed method enables accurate concentrations together with reasonable resolution of excitation and emission profiles for the analytes of interest. An additional advantage of the proposed method is that there is no need for separation and sample pretreatment, in addition to lower cost than traditional methods.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-1 Receptor Antagonists / blood*
  • Adrenergic beta-1 Receptor Antagonists / metabolism
  • Adrenergic beta-1 Receptor Antagonists / therapeutic use
  • Algorithms
  • Blood Chemical Analysis / methods*
  • Calibration
  • Cardiovascular Diseases / drug therapy
  • Humans
  • Kinetics
  • Metoprolol / analogs & derivatives*
  • Metoprolol / blood*
  • Metoprolol / standards
  • Metoprolol / therapeutic use
  • Oxidation-Reduction
  • Spectrometry, Fluorescence* / standards

Substances

  • Adrenergic beta-1 Receptor Antagonists
  • alpha-hydroxymetoprolol
  • Metoprolol